BLI Banque de Luxembourg Investments Raises Stock Holdings in Abbott Laboratories $ABT

BLI Banque de Luxembourg Investments lifted its holdings in Abbott Laboratories (NYSE:ABT) by 10.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 200,725 shares of the healthcare product maker’s stock after buying an additional 18,344 shares during the quarter. BLI Banque de Luxembourg Investments’ holdings in Abbott Laboratories were worth $25,255,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ABT. Brighton Jones LLC increased its holdings in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC increased its holdings in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the period. United Bank increased its holdings in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after purchasing an additional 2,001 shares during the period. Main Street Financial Solutions LLC increased its holdings in Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after purchasing an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board increased its holdings in Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock worth $195,267,000 after purchasing an additional 292,547 shares during the period. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Down 0.7%

Shares of NYSE:ABT opened at $90.46 on Tuesday. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The business’s fifty day simple moving average is $92.52 and its 200-day simple moving average is $108.88. The company has a market capitalization of $157.57 billion, a PE ratio of 25.34, a P/E/G ratio of 1.52 and a beta of 0.63. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same period last year, the business posted $1.09 EPS. The business’s revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on ABT. JPMorgan Chase & Co. reduced their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Bank of America reduced their price objective on Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Jefferies Financial Group reduced their price objective on Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Argus cut their price target on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Finally, Citigroup cut their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and an average price target of $119.09.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction dated Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director directly owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.